GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (HAM:MYD) » Definitions » Cyclically Adjusted PS Ratio

Myriad Genetics (HAM:MYD) Cyclically Adjusted PS Ratio : 0.36 (As of May. 22, 2025)


View and export this data going back to 1995. Start your Free Trial

What is Myriad Genetics Cyclically Adjusted PS Ratio?

As of today (2025-05-22), Myriad Genetics's current share price is €3.74. Myriad Genetics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €10.48. Myriad Genetics's Cyclically Adjusted PS Ratio for today is 0.36.

The historical rank and industry rank for Myriad Genetics's Cyclically Adjusted PS Ratio or its related term are showing as below:

HAM:MYD' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.34   Med: 2.76   Max: 8.07
Current: 0.35

During the past years, Myriad Genetics's highest Cyclically Adjusted PS Ratio was 8.07. The lowest was 0.34. And the median was 2.76.

HAM:MYD's Cyclically Adjusted PS Ratio is ranked better than
87.12% of 132 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.06 vs HAM:MYD: 0.35

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Myriad Genetics's adjusted revenue per share data for the three months ended in Mar. 2025 was €1.983. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €10.48 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Myriad Genetics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Myriad Genetics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Cyclically Adjusted PS Ratio Chart

Myriad Genetics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.20 2.59 1.28 1.67 1.20

Myriad Genetics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.84 2.12 2.38 1.20 0.77

Competitive Comparison of Myriad Genetics's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Myriad Genetics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myriad Genetics's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Cyclically Adjusted PS Ratio falls into.


;
;

Myriad Genetics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Myriad Genetics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=3.74/10.48
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Myriad Genetics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Myriad Genetics's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.983/134.9266*134.9266
=1.983

Current CPI (Mar. 2025) = 134.9266.

Myriad Genetics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 2.327 100.684 3.118
201509 2.268 100.392 3.048
201512 2.404 99.792 3.250
201603 2.327 100.470 3.125
201606 2.082 101.688 2.763
201609 2.299 101.861 3.045
201612 2.727 101.863 3.612
201703 2.695 102.862 3.535
201706 2.015 103.349 2.631
201709 2.131 104.136 2.761
201712 2.208 104.011 2.864
201803 2.051 105.290 2.628
201806 2.277 106.317 2.890
201809 2.375 106.507 3.009
201812 2.491 105.998 3.171
201903 2.559 107.251 3.219
201906 2.549 108.070 3.182
201909 2.295 108.329 2.858
201912 2.360 108.420 2.937
202003 1.992 108.902 2.468
202006 1.109 108.767 1.376
202009 1.650 109.815 2.027
202012 1.694 109.897 2.080
202103 1.913 111.754 2.310
202106 2.036 114.631 2.396
202109 1.745 115.734 2.034
202112 1.777 117.630 2.038
202203 1.869 121.301 2.079
202206 2.110 125.017 2.277
202209 1.957 125.227 2.109
202212 2.067 125.222 2.227
202303 2.082 127.348 2.206
202306 2.073 128.729 2.173
202309 2.195 129.860 2.281
202312 2.087 129.419 2.176
202403 2.069 131.776 2.118
202406 2.169 132.554 2.208
202409 2.114 133.029 2.144
202412 2.213 133.157 2.242
202503 1.983 134.927 1.983

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Myriad Genetics  (HAM:MYD) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Myriad Genetics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Myriad Genetics Business Description

Traded in Other Exchanges
Address
322 North 2200 West, Salt Lake City, UT, USA, 84116
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.